Flow Diverter Stent System
Clinical Trial- Indications
- Cerebral aneurysms
Company intelligence / Profile preview
Sinomed Neurovita Technology is an active Chinese medical technology subsidiary specializing in innovative interventional neurovascular devices—most notably the world’s first healing-targeted intracranial drug-eluting stents—for treatment of conditions like intracranial atherosclerotic stenosis and acute ischemic stroke. It operates under the umbrella of Sino Medical Sciences Technology ("SINOMED"), which is publicly traded on the Shanghai STAR Market since November 2019. The company's pipeline includes several advanced catheters/stents now approved or undergoing late-stage clinical evaluation both within China and internationally through its global network.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sinomed Neurovita Technology.